Clinical trial
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who…
NCT00101660 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00101660 |
|---|---|
| Title | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib |
| Official title | A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 387 |
| Start date | Feb 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Apr 1, 2008 |
| First posted | Jan 13, 2005 |
| Last update posted | Mar 2, 2012 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Netherlands and 10 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: